Rare bleeding disorder study seeks to unlock antibody mystery

NCT ID NCT04595617

Completed Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 28 people with Glanzmann thrombasthenia, a rare bleeding disorder, to understand why some develop harmful antibodies after blood transfusions or pregnancy. Researchers checked for antibodies every six months and after each transfusion over 18 months. The goal was to link genetic, treatment, and lifestyle factors to antibody formation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors predict and reduce the risk of antibody formation in Glanzmann thrombasthenia patients, improving transfusion safety.
What could go wrong: This is a small observational study (28 people) that only measures antibodies, not a treatment. It may not lead to direct changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLANZMANN THROMBASTHENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Glanzmann thrombasthenia Glanzmann thrombasthenia 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLANZMANN THROMBASTHENIA

Contacts and locations

Locations

CHU Bordeaux - Hôpital Haut-Lévêque

Bordeaux, France
CHU Bordeaux - Hôpital Pellegrin

Bordeaux, France
CHU Nîmes

Nîmes, France
CHU Strasbourg

Strasbourg, France
CHU Toulouse

Toulouse, France
Hôpital Bicêtre, APHP

Le Kremlin-Bicêtre, France
Hôpital la Timone, APHM

Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.